Skip to main content
Clinical Trials/NCT05616299
NCT05616299CompletedNot Applicable

Human Clinical Trial to Evaluate the BRIGHTPOINT Reflectometer Device as Secondary Confirmation to Loss of Resistance in Lumbar Epidural Placement

University Hospitals Cleveland Medical Center1 site in 1 country3 target enrollmentStarted: April 28, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
3
Locations
1
Primary Endpoint
Number of times the BrightPoint device was able to measure Loss of Residence (LOR) accurately.

Study Overview

Brief Summary

Participants are being asked to participate in this study because they are having an epidural placed for labor. This human clinical trial has been designed to evaluate the use of the BrightPoint Reflectometer Device (AKA BrightPoint device) as secondary confirmation of Loss of Residence (LOR) for lumbar epidural placement by an experienced clinician. For this study, participants will be randomized to receive an epidural by an experienced clinician either with or without the use of the BrightPoint device. Epidurals performed as a part of this study will be done in a manner similar to how epidurals are currently performed in the hospital. The epidural space will be entered using usual loss of resistance technique for all patients. If the BrightPoint device is used, it will be as secondary verification of entry into the epidural space.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Device Feasibility
Masking
None

Eligibility Criteria

Ages
18 Years to 79 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Any patient undergoing an epidural procedure

Exclusion Criteria

  • •Previous lumbar spine surgery
  • •Any known spinal abnormality that would interferre with successfully advancing a needle into the epidural space
  • •Any subject that requires an epidural needle longer than 4.0 inches
  • •Any procedure requiring use of CSE needles
  • •Any contraindication to neuraxial anesthesia
  • •No subjects in advanced active labor, e.g., 6-8 cm dilated
  • •Tattoo at the site of epidural insertion

Arms & Interventions

BrightPoint Epidural

Experimental

Subjects will receive an epidural using the BrightPoint device concurrent with usual LOR technique using the same epidural needle, sterile saline, syringe, etc.

Intervention: BrightPoint (Device)

Normal Epidural

No Intervention

Subjects will have an epidural placed in usual manner with LOR technique using the same epidural needle, sterile saline, syringe etc. but without use of the BrightPoint device.

Outcomes

Primary Outcomes

Number of times the BrightPoint device was able to measure Loss of Residence (LOR) accurately.

Time Frame: Up to 90 minutes

This is measured as a Yes or No response.

Secondary Outcomes

  • Number of times the BrightPoint device provided real-time secondary confirmation of Loss of Residence (LOR) as measured by clinician log(Up to 90 minutes)
  • Number of times the BrightPoint device provided beneficial qualitative/quantitative clinical information to help complete the epidural as measured by clinician log.(Up to 90 minutes)
  • Number of times the device indicated the needle tip was entering the LF as measured by clinician log(Up to 20 minutes)
  • Number of times the device showed a significant change of reflectance from high in LF to low in ES as measured by clinician log(Up to 90 minutes)
  • Number of times the LOR and BrightPoint device agreed as measured by clinician log(Up to 90 minutes)
  • Number of adverse events as measured by clinician log(Up to 90 minutes)
  • Number of times epidural accessed while using BrightPoint device as measured by clinical log(Up to 90 minutes)
  • Number of times epidural catheter was used during the procedure as measured by clinical log(Up to 20 minutes)
  • Number of times clinician experienced LOR after entering the epidural space as measured by clinician log(Up to 90 minutes)
  • Number of times clinician experienced the haptic sensation of the needle contacting any tissue that was not expected as measured by clinician log(Up to 90 minutes)
  • Number of times there were issues with catheterization as measured by clinician log(Up to 90 minutes)
  • Number of times coring was observed during procedure as measured by clinician log(Up to 90 minutes)
  • Number of times the BrightPoint interfered with the ability to perform the epidural placement in the usual manner with LOR and haptic feedback as measured by clinician log(Up to 90 minutes)
  • Number of times clinician experienced the haptic feel of entering the ligamentum flavum (LF) as measured by clinician log(Up to 90 minutes)
  • Number of times there were issues achieving pain management as measured by clinician log(Up to 4 hours)
  • Number of times the device showed a significant change of color from the light in LF to the dark in ES as measured by clinician log(Up to 90 minutes)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials